184 related articles for article (PubMed ID: 29627895)
21. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
22. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
23. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
[TBL] [Abstract][Full Text] [Related]
24. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
27. Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells.
Li Y; Chen X; He W; Xia S; Jiang X; Li X; Bai J; Li N; Chen L; Yang B
Nutr Cancer; 2021; 73(8):1489-1497. PubMed ID: 32757802
[TBL] [Abstract][Full Text] [Related]
28. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
29. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
30. A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.
Gaudio E; Paduano F; Ngankeu A; Ortuso F; Lovat F; Pinton S; D'Agostino S; Zanesi N; Aqeilan RI; Campiglia P; Novellino E; Alcaro S; Croce CM; Trapasso F
Oncotarget; 2016 May; 7(21):29927-36. PubMed ID: 27166255
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML.
Yang B; Yao J; Li B; Shao G; Cui Y
Mol Cell Biochem; 2017 Dec; 436(1-2):87-97. PubMed ID: 28744813
[TBL] [Abstract][Full Text] [Related]
32. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
33. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer.
Choi CH; Chung JY; Chung EJ; Sears JD; Lee JW; Bae DS; Hewitt SM
BMC Cancer; 2016 Jul; 16():448. PubMed ID: 27402115
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
36. MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN.
Li Y; Li L; Guan Y; Liu X; Meng Q; Guo Q
Biochem Biophys Res Commun; 2013 Nov; 440(4):604-10. PubMed ID: 24099768
[TBL] [Abstract][Full Text] [Related]
37. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
38. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
Zhang MC; Hu CP; Chen Q
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
[TBL] [Abstract][Full Text] [Related]
39. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
40. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]